H-Index
75
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
18%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

Get your full text copy in PDF

A phase I study of a six-week cycle of immunotherapy with Murabutide in HIV-1 patients na¨Ive to antiretrovirals

Xavier De La Tribonniere, Yves Mouton, Vincent Vidal, Edith Darcissac, Daouda Sissoko, Clothilde Fontier, Youcef Douadi, Joƫlle Dewulf, Corinne Amiel, George Michael Bahr

Med Sci Monit 2003; 9(6): PI43-50

ID: 12743


Background:Limitations in the use of antiretroviral therapy suggest the need for additional approaches to enhance immune restoration and the control of HIV-1 replication. Therefore, we evaluated the clinical tolerance and biological effects of immunotherapy with the synthetic immunomodulator Murabutide in 9 treatment-na¨lve HIV-1 patients presenting with CD4+ lymphocyte counts >500 cells/mm3 and plasma viral loads

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree